Marina Biotech, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference

BOTHELL, WA--(Marketwire - March 8, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, announced today that it will present at the ROTH 23^rd Annual OC Growth Stock Conference on Tuesday, March 15, 2011, at 4:00 p.m. Eastern Time (1:00 p.m. Pacific Time) at the Ritz-Carlton in Laguna Niguel, CA. J. Michael French, Marina Biotech President and Chief Executive Officer, will present a corporate overview and business update. 

A live audio webcast will be available on the Event Calendar pages of the Investors section of the Company's website at http://www.marinabio.com. Please allow time prior to the presentation to register and download any necessary software. A replay of the presentation will be available on the Investors section of the Marina Biotech website under Event Calendar approximately one hour after the live presentation.

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company, focused on the development and commercialization of RNA interference- (RNAi) and RNA-based therapeutics. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech has recently entered an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi- and RNA-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

Contact Information:

Contact:
Marina Biotech, Inc.:
Pete Garcia
Chief Financial Officer
(425) 908-3603